Related references
Note: Only part of the references are listed.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma
Vincenzo Mazzaferro et al.
GASTROENTEROLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria)
Josep M. Llovet et al.
LIVER TRANSPLANTATION (2018)
The immunology of hepatocellular carcinoma
Marc Ringelhan et al.
NATURE IMMUNOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation
Min Xu et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015
Tomi Akinyemiju et al.
JAMA ONCOLOGY (2017)
Predicting Mortality in Patients Developing Recurrent Hepatocellular Carcinoma After Liver Transplantation Impact of Treatment Modality and Recurrence Characteristics
Adam S. Bodzin et al.
ANNALS OF SURGERY (2017)
Recurrence After Liver Transplantation for Hepatocellular Carcinoma A New MORAL to the Story
Karim J. Halazun et al.
ANNALS OF SURGERY (2017)
Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma
Pei-Pei Song et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma
Davide Citterio et al.
JAMA SURGERY (2016)
Recurrence of Hepatocellular Cancer After Resection Patterns, Treatments, and Prognosis
Parissa Tabrizian et al.
ANNALS OF SURGERY (2015)
A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Analysis of 865 Consecutive Liver Transplant Recipients
Vatche G. Agopian et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2015)
Combinations of Biomarkers and Milan Criteria for Predicting Hepatocellular Carcinoma Recurrence After Liver Transplantation
Roongruedee Chaiteerakij et al.
LIVER TRANSPLANTATION (2015)
Prognostic Role of Plasma Vascular Endothelial Growth Factor in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation
Wei Zhang et al.
LIVER TRANSPLANTATION (2015)
Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Virginia Hernandez-Gea et al.
GASTROENTEROLOGY (2013)
Resection of hepatocellular cancer ≤2 cm: Results from two Western centers
Sasan Roayaie et al.
HEPATOLOGY (2013)
Dysfunctional Activation of Neurotensin/IL-8 Pathway in Hepatocellular Carcinoma Is Associated with Increased Inflammatory Response in Microenvironment, More Epithelial Mesenchymal Transition in Cancer and Worse Prognosis in Patients
Jinpu Yu et al.
PLOS ONE (2013)
Pretransplantation α-Fetoprotein Slope and Milan Criteria: Strong Predictors of Hepatocellular Carcinoma Recurrence After Transplantation
Teodora C. Dumitra et al.
TRANSPLANTATION (2013)
Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria
Christophe Duvoux et al.
GASTROENTEROLOGY (2012)
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report
Pierre-Alain Clavien et al.
LANCET ONCOLOGY (2012)
Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value
Andrew X. Zhu et al.
CLINICAL CANCER RESEARCH (2011)
HCC and angiogenesis: possible targets and future directions
Andrew X. Zhu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets
Ju Dong Yang et al.
SEMINARS IN CANCER BIOLOGY (2011)
Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer
Dan G. Duda et al.
ONCOLOGIST (2010)
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria
Christian Toso et al.
TRANSPLANT INTERNATIONAL (2009)
Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: Possible association with hepatic function impairment
Jerzy Jaroszewicz et al.
CYTOKINE (2008)
VEGFR3: A new target for antiangiogenesis therapy?
Timothy P. Padera et al.
DEVELOPMENTAL CELL (2008)
Angiogenesis in liver cirrhosis and hepatocellular carcinoma
Anjali D. Amarapurkar et al.
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY (2008)
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
Tuomas Tammela et al.
NATURE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
Yujin Hoshida et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The wolf in sheep's clothing: the role of interieukin-6 in immunity, inflammation and cancer
Willscott E. Naugler et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis
Alessandro Cucchetti et al.
LIVER TRANSPLANTATION (2006)
Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma
R Yamaguchi et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2006)
Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer
H Bando et al.
BRITISH JOURNAL OF CANCER (2005)
Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery
Y Chao et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma
GY Chau et al.
ANNALS OF SURGERY (2000)
Share Paper
